Docket
117th Congress · HOUSE BILLBILL

H.R. 2891 — Preserve Access to Affordable Generics and Biosimilars Act

“To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market.”

Health
Introduced Apr 28, 2021
Last action Sep 29, 2021
Pipeline · Bill → Law
Step 1
Introduced
Apr 28, 2021
Step 2
Referred
Apr 29, 2021
E&C · Judiciary
Step 3
Committee
Sep 29, 2021
Reported out
Step 4
House floor
Step 5
Senate
Step 6
Resolve Changes
Step 7
Signed
SummaryNo summary available

No CRS summary available for this bill.

Provisions · 10 sectionsReported to House
Timeline · 6 actions
Sep 29, 2021
Committee Consideration and Mark-up Session Held.
Sep 29, 2021
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 13.
Apr 29, 2021
Referred to the Subcommittee on Health.
Apr 28, 2021
Introduced in House
Apr 28, 2021
Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 28, 2021
Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.